Taisun Biotech Corrects Errors in Its Q1 2026 Consolidated Financial Report
On May 20, 2026, Taisun Biotechnology Co., Ltd. announced a correction to its Q1 2026 consolidated financial report due to clerical errors. The correction pertains to the cash flow statement, rectifying an incorrect sign for "Interest expense" and "Interest paid," and addressing the omission of "Interest income" and "Interest received." The corresponding iXBRL filing has also been corrected.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 09:00
- 🔍 Collected: May 21, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 21, 2026 at 08:32 (31 min after Collected)
1. Date of occurrence: 2026/05/20
2. Company name: Taisun Biotechnology Co., Ltd.
3. Relationship to the company (please enter 'this company' or 'subsidiary'): This company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence:
Incorrect positive/negative sign for "Interest expense" and "Interest paid" in the Q1 2026 Cash Flow Statement.
Omission of "Interest income" and "Interest received".
6. Corrected information item/report name:
Company's Q1 2026 consolidated financial report, Q1 2026 iXBRL filing information
7. Pre-correction amount/content/page:
Cash Flow Statement Page 10
Jan 1, 2026 Jan 1, 2025
to Mar 31 to Mar 31
----------------------------------------------------
Interest expense ( 166) ( 226)
Interest paid 166 226
8. Post-correction amount/content/page:
Cash Flow Statement Page 10
Jan 1, 2026 Jan 1, 2025
to Mar 31 to Mar 31
----------------------------------------------------
Interest expense 166 226
Interest income ( 1,114) ( 1,121)
Interest received 1,114 1,121
Interest paid ( 166)
2. Company name: Taisun Biotechnology Co., Ltd.
3. Relationship to the company (please enter 'this company' or 'subsidiary'): This company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence:
Incorrect positive/negative sign for "Interest expense" and "Interest paid" in the Q1 2026 Cash Flow Statement.
Omission of "Interest income" and "Interest received".
6. Corrected information item/report name:
Company's Q1 2026 consolidated financial report, Q1 2026 iXBRL filing information
7. Pre-correction amount/content/page:
Cash Flow Statement Page 10
Jan 1, 2026 Jan 1, 2025
to Mar 31 to Mar 31
----------------------------------------------------
Interest expense ( 166) ( 226)
Interest paid 166 226
8. Post-correction amount/content/page:
Cash Flow Statement Page 10
Jan 1, 2026 Jan 1, 2025
to Mar 31 to Mar 31
----------------------------------------------------
Interest expense 166 226
Interest income ( 1,114) ( 1,121)
Interest received 1,114 1,121
Interest paid ( 166)